Lu sur : https://journals.lww.com/neurotodayonli ... vis.4.aspx
Traduction disponible directement en cliquant sur "Sélectionner une langue" dans la barre des menus"
COVID-19: Guidelines for Myasthenia Gravis Management and other Neuromuscular Disorders
By Richard Robinson
May 21, 2020
Article In Brief
A panel of experts on myasthenia gravis and Lambert-Eaton myasthenic syndrome pulled together a consensus document, based on what is known to date, on how to manage these neuromuscular diseases during the COVID19 pandemic.
If your patients have myasthenia gravis, should they come in for an infusion therapy? Is it safe to start patients on a new B-cell depleting therapy? And should patients stop their immunosuppressive therapies? As the COVID-19 pandemic rages on, neurologists working with patients with neuromuscular diseases are fielding these questions with little overall specific data on the overall effect of the virus on patients with these neuromuscular conditions.
In an effort to answer those questions based on what is known to date, a panel of experts has published new guidelines to treat myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) in the setting of the novel coronavirus.